Hematopoietic and Lymphatic System NeoplasmNCT07737314
Tele-HOPE: A Telehealth Pharmacist Opioid Patient Education Pilot Study
A study testing Survey Administration and Electronic Health Record Review in people with Hematopoietic and Lymphatic System Neoplasm and Malignant Solid Neoplasm, run by Fred Hutchinson Cancer Center at 1 site in United States.
Trial summary
This clinical trial will evaluate the feasibility, acceptability, and potential efficacy of a palliative care pharmacist-led group telehealth opioid education session for palliative care patients prescribed opioids for cancer-related pain. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
- What is being tested?
- Survey Administration and Electronic Health Record Review
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- 3 Nov 2026to 31 Aug 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years, consistent with the population of patients treated at Fred Hutch Cancer Center
- A cancer diagnosis
- Established care in the Fred Hutch Palliative Care Clinic (≥ 1 visit with a Fred Hutch palliative care physician or advanced practice provider within the past 12 months)
- Prescribed opioids, defined as either ≥ 1 opioid prescription within the past 6 months documented in the Washington Prescription Drug Monitoring Program (PDMP), or a new opioid prescription initiated by the referring palliative care provider at the time of referral
- Ability to understand and willingness to agree to an electronic consent document
- Enrolled in MyChart and ability to participate in a telehealth video visit
Who cannot join
- Patients who prefer a language other than English for healthcare, as the session will be conducted live and cannot currently be offered in other languages
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109
Sheri Ballard, 206-667-4222, sballard@fredhutch.org
Nicole Dussault, MD, MS
About this study
This clinical trial will evaluate the feasibility, acceptability, and potential efficacy of a palliative care pharmacist-led group telehealth opioid education session for palliative care patients prescribed opioids for cancer-related pain. While opioids are commonly used in palliative care settings to manage cancer-related pain, their significant side effects, complicated administration requirements, and concerns about addiction can make it challenging for patients to use opioids safely and effectively. Some patients may even avoid opioids altogether because of these concerns, even when opioids are clinically indicated, leading to poor symptom control. To address these challenges, a telehealth education session was developed as a clinical initiative by a palliative care pharmacist, addressing safe and effective opioid management. Educational priorities and session content were informed by a survey of interdisciplinary palliative care clinicians that identified barriers and facilitators to opioid education and key patient educational needs. Patients scheduled to attend a pharmacist-led group telehealth opioid education session who enroll in the study will complete a survey before the session and another survey afterward. This study will assess the feasibility and acceptability of delivering the intervention, as well as its preliminary effects on opioid knowledge and self-efficacy. If feasible and acceptable, this pharmacist-led telehealth education model could represent a scalable strategy to improve opioid management for patients with cancer-related pain.
Read the detailed description
OUTLINE:
Patients scheduled to attend a pharmacist-led group telehealth opioid education session who enroll in the study will complete a survey before the session and another survey afterward. After attending the pharmacist education session, patients will receive a patient education handout summarizing the educational content.
After attending the pharmacist education session, participants will complete the final survey within 1 month, concluding their participation.
- Being tested
- Survey Administration, Electronic Health Record Review
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Survey AdministrationOther
Ancillary studies - pre- and post-session surveys to assess opioid knowledge and self-efficacy, and post-session to assess session acceptability
Electronic Health Record ReviewOther
Ancillary studies
| Study group | Role | What they receive |
|---|---|---|
| Supportive care (pharmacist-led opioid education session) | Experimental | Patients scheduled to attend a pharmacist-led group telehealth opioid education session who enroll in the study will complete a survey before the session and another survey afterward. After attending the pharmacist education session, patients will receive a patient education handout summarizing the educational content. Receives: Other: Survey Administration; Other: Electronic Health Record Review |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of referred patients who attend pharmacist education session (Feasibility)
Feasibility of the pharmacist education session will be interpreted as an overall session attendance-to-referral rate ≥ 50%.
Measured: Up to 6 months
Participant score on the "general acceptability" item of the Theoretical Framework of Acceptability questionnaire
Assessed on post-session surveys, delivered within 7 days after session attendance, with up to one month of follow-up to encourage survey completion. Acceptability of the pharmacist education session will be interpreted as > 70% respondents rating the sessions as ≥ 4/5 (i.e. "acceptable" or "completely acceptable") on the "general acceptability" item of the Theoretical Framework of Acceptability scale (5 point Likert scale), assessed on the post-session survey.
Measured: Up to 1 month post-session
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jul 2026
- Study start3 Nov 2026
- Primary completion31 Jul 2027 (estimated)
- Study completion31 Aug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hematopoietic and Lymphatic System NeoplasmStudies of the same condition, open and under way.
- More trials run by Fred Hutchinson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fred Hutchinson Cancer Center
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Nicole Dussault, MD, MS, Principal investigator, Fred Hutch/University of Washington Cancer Consortium
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07737314
- Sponsor's protocol ID
- RG1126526
- Other IDs
- NCI-2026-05093, 0021316, P30CA015704
- Status last verified
- Jul 2026
- First submitted
- 27 Jul 2026
- Last updated
- 6 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: This study will generate quantitative and qualitative human subjects data as part of a pilot evaluation of a palliative care pharmacist-led group telehealth opioid education session intervention for patients with cancer pain. Quantitative data will include structured survey responses and electronic health record data. The shared data package will include de-identified quantitative datasets, qualitative data files where appropriate, data dictionaries/codebooks, and copies of study instruments, subject to instrument licensing requirements. De-identified datasets will be preserved and shared via a suitable repository that supports health-related research data, such as a general-purpose repository (e.g., Dryad or Figshare) or an institutional repository supported by Fred Hutchinson Cancer Center. The selected repository will provide persistent identifiers (e.g., DOIs) to support citation and long-term access.
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Tele-HOPE: A Telehealth Pharmacist Opioid Patient Education Pilot Study
- ClinicalTrials.gov ID
- NCT07737314
- Acronym / sponsor ID
- RG1126526
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Fred Hutchinson Cancer CenterUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 3 Nov 2026 (actual)
- Primary completion
- 31 Jul 2027 (estimated)
- Study completion
- 31 Aug 2027 (estimated)
- First posted
- 30 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical trial will evaluate the feasibility, acceptability, and potential efficacy of a palliative care pharmacist-led group telehealth opioid education session for palliative care patients prescribed opioids for cancer-related pain. While opioids are commonly used in palliative care settings to manage cancer-related pain, their significant side effects, complicated administration requirements, and concerns about addiction can make it challenging for patients to use opioids safely and effectively. Some patients may even avoid opioids altogether because of these concerns, even when opioids are clinically indicated, leading to poor symptom control. To address these challenges, a telehealth education session was developed as a clinical initiative by a palliative care pharmacist, addressing safe and effective opioid management. Educational priorities and session content were informed by a survey of interdisciplinary palliative care clinicians that identified barriers and facilitators to opioid education and key patient educational needs. Patients scheduled to attend a pharmacist-led group telehealth opioid education session who enroll in the study will complete a survey before the session and another survey afterward. This study will assess the feasibility and acceptability of delivering the intervention, as well as its preliminary effects on opioid knowledge and self-efficacy. If feasible and acceptable, this pharmacist-led telehealth education model could represent a scalable strategy to improve opioid management for patients with cancer-related pain.
Detailed description
OUTLINE:
Patients scheduled to attend a pharmacist-led group telehealth opioid education session who enroll in the study will complete a survey before the session and another survey afterward. After attending the pharmacist education session, patients will receive a patient education handout summarizing the educational content.
After attending the pharmacist education session, participants will complete the final survey within 1 month, concluding their participation.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Supportive care (pharmacist-led opioid education session) | Experimental | Other: Survey Administration, Other: Electronic Health Record ReviewPatients scheduled to attend a pharmacist-led group telehealth opioid education session who enroll in the study will complete a survey before the session and another survey afterward. After attending the pharmacist education session, patients will receive a patient education handout summarizing the educational content. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age ≥ 18 years, consistent with the population of patients treated at Fred Hutch Cancer Center
- A cancer diagnosis
- Established care in the Fred Hutch Palliative Care Clinic (≥ 1 visit with a Fred Hutch palliative care physician or advanced practice provider within the past 12 months)
- Prescribed opioids, defined as either ≥ 1 opioid prescription within the past 6 months documented in the Washington Prescription Drug Monitoring Program (PDMP), or a new opioid prescription initiated by the referring palliative care provider at the time of referral
- Ability to understand and willingness to agree to an electronic consent document
Key exclusion criteria (1 listed)
- Patients who prefer a language other than English for healthcare, as the session will be conducted live and cannot currently be offered in other languages
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Survey AdministrationAncillary studies - pre- and post-session surveys to assess opioid knowledge and self-efficacy, and post-session to assess session acceptability | Other | Supportive care (pharmacist-led opioid education session) |
| Electronic Health Record ReviewAncillary studies | Other | Supportive care (pharmacist-led opioid education session) |
Primary outcome
Percentage of referred patients who attend pharmacist education session (Feasibility)
Time frame: Up to 6 months
Feasibility of the pharmacist education session will be interpreted as an overall session attendance-to-referral rate ≥ 50%.
Participant score on the "general acceptability" item of the Theoretical Framework of Acceptability questionnaire
Time frame: Up to 1 month post-session
Assessed on post-session surveys, delivered within 7 days after session attendance, with up to one month of follow-up to encourage survey completion. Acceptability of the pharmacist education session will be interpreted as > 70% respondents rating the sessions as ≥ 4/5 (i.e. "acceptable" or "completely acceptable") on the "general acceptability" item of the Theoretical Framework of Acceptability scale (5 point Likert scale), assessed on the post-session survey.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
- Individual participant dataSharing planned: Yes. This study will generate quantitative and qualitative human subjects data as part of a pilot evaluation of a palliative care pharmacist-led group telehealth opioid education session intervention for patients with cancer pain. Quantitative data will include structured survey responses and electronic health record data. The shared data package will include de-identified quantitative datasets, qualitative data files where appropriate, data dictionaries/codebooks, and copies of study instruments, subject to instrument licensing requirements. De-identified datasets will be preserved and shared via a suitable repository that supports health-related research data, such as a general-purpose repository (e.g., Dryad or Figshare) or an institutional repository supported by Fred Hutchinson Cancer Center. The selected repository will provide persistent identifiers (e.g., DOIs) to support citation and long-term access.
Related trials for Hematopoietic and Lymphatic System Neoplasm
RecruitingObservational study
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Leukemia, Lymphoma
Active, not recruitingPhase 2
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
Active, not recruitingPhase 2
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Nicole Dussault, MD, MS principal investigator
Fred Hutch/University of Washington Cancer Consortium
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Survey Administration and Electronic Health Record Review in people with Hematopoietic and Lymphatic System Neoplasm and Malignant Solid Neoplasm, run by Fred Hutchinson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sheri Ballard (206-667-4222, sballard@fredhutch.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of referred patients who attend pharmacist education session (Feasibility) (time frame: Up to 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.